Supernus Pharmaceuticals (FRA:S49) Short Interest

View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Supernus Pharmaceuticals's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Supernus Pharmaceuticals's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Short Interest falls into.

Supernus Pharmaceuticals (FRA:S49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

SUPN:USA S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (FRA:S49) Headlines

No Headlines